Impileo Lifescience pvt ltd

Pcd Pharma Franchise | Third Party Manufacturing

19. October 2020 15:52
by Administrator
0 Comments

Piperacillin 4mg Tazobactam 500mg

19. October 2020 15:52 by Administrator | 0 Comments

Piperacillin 4mg Tazobactam 500mg called also Piperacillin Tazobactam 4.5 injection available in pcd pharma franchise with brand name PERTH 4.5 and also 

 

provide in third party manufacturing.

 

 

PERTH 4.5

Composition : Piperacillin 4mg, Tazobactam 500mg

Piperacillin :Piperacillin is a broad spectrum β-lactam antibiotic of the ureidopenicillins class.

Tazobactam: Tazobactam is a pharmaceutical drug that inhibits the action of bacterial β-lactamases.

Mode Of Action :-

Piperacillin:  Tazobactam is given with Piperacillin  to enhance the activity of Piperacillin  in eradicating bacterial infections. Piperacillin  kills bacteria by inhibiting the synthesis of bacterial cell walls. It binds  preferentially to specific penicillin –binding protein (PBPs)located inside bacterial cell walls.

Tazobactam:  Tazobactam is as a β-lactamases inhibitor. It is a penicillanic acid sulfone derivative and β-lactamases inhibitor with antibacterial activity. It contain β-lactam ring and irreversibly binds to β-lactamases at or near its active site.

Indications and usage:-

Piperacillin:    

  • It is used to treat urinary tract infections
  • Bone and joint infections
  • Severe vaginal infections
  • Stomach infections
  • Skin infections
  • Pneumonia

Tazobactam:

  • It is used to treat urinary tract infections
  • Bone and joint infections
  • Severe vaginal infections
  • Stomach infections
  • Skin infections
  • Pneumonia

Side effects:-

Piperacillin:  Common side effect:

  • Vomiting
  • Diarrhea
  • Constipation
  • Rash/itching
  • Pain at site of injection
  • Runny nose
  • Agitation
  • Stomach pain
  • Insomnia

Tazobactam:  Common side effect:

  • Vomiting
  • Diarrhea
  • Constipation
  • Rash/itching
  • Pain at site of injection
  • Runny nose
  • Agitation
  • Stomach pain
  • Insomnia
Comments are closed